More recently, GSK3β is studied as a promising target for anti-cancer treatment with supporting preclinical data in a number of malignancies, including pancreatic cancer, colon cancer, bladder cancer, kidney cancer, and melanoma (18). Here, GSK3B is linked to melanoma.